Horses for courses: Reaching outside drug-like chemical space for inhibitors of challenging drug targets

Future Medicinal Chemistry

Volumn 7, Issue 9, 2015, Pages 1093-1095

  Whitty, Adrian ^a   Zhou, Li ^a  

^a USA   (United States)

Author keywords

ADME; covalent inhibitors; druggability; druglikeness; foldamers; macrocycles; protein protein interactions

Indexed keywords

CARBOHYDRATE BINDING PROTEIN; CYCLOPEPTIDE; DNA BINDING PROTEIN; INTRINSICALLY DISORDERED PROTEIN; MACROCYCLIC COMPOUND; NATURAL PRODUCT; PEPTIDE; BIOLOGICAL PRODUCT; DRUG; PROTEIN; PROTEIN BINDING;

CLINICAL FEATURE; COVALENT BOND; DRUG ABSORPTION; DRUG BINDING SITE; DRUG COST; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG TARGETING; HORSE; MEMBRANE PERMEABILITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW;

BIOLOGICAL PRODUCTS; MACROCYCLIC COMPOUNDS; PEPTIDES; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEINS;

EID: 84935048919     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.56     Document Type: Review

References (13)

1. Ganesan A. The impact of natural products upon modern drug discovery. Curr. Opin. Chem. Biol. 12, 306-317 (2008).
2. Schreiber SL. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287, 1964-1969 (2000).
3. Koch MA, Schuffenhauer A, Scheck M et al. Charting biologically relevant chemical space: a structural classifcation of natural products (SCONP). Proc. Natl Acad. Sci. USA 102, 17272-17277 (2005).
4. Driggers EM, Hale SP, Lee J, Terrett NK. The exploration of macrocycles for drug discovery-an underexploited structural class. Nat. Rev. Drug Discov. 7, 608-624 (2008).
5. Giordanetto F, Kihlberg J. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? J. Med. Chem. 57, 278-295 (2014).
6. Villar EA, Beglov D, Chennamadhavuni S et al. How proteins bind macrocycles. Nat. Chem. Bio. 10, 723-731 (2014).
7. Bockus AT, McEwen CM, Lokey RS. Form and function in cyclic peptide natural products: a pharmacokinetic perspective. Curr. Top. Med. Chem. 13, 821-836 (2013).
8. Hewitt WM, Leung SS, Pye CR et al. Cell-permeable cyclic peptides from synthetic libraries inspired by natural products. J. Am. Chem. Soc. 137, 715-721 (2015).
9. Bautista AD, Craig CJ, Harker EA, Schepartz A. Sophistication of foldamer form and function in vitro and in vivo. Curr. Opin. Chem. Biol. 11, 685-692 (2007).
10. Aileron Therapeutics Initiates Phase 1 Cancer Study of ALRN-6924 in Advanced Hematologic and Solid Malignancies with Wild Type p53. www.businesswire.com
11. Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10, 307-317 (2011).
12. Copeland RA. The dynamics of drug-target interactions: drug-target residence time and its impact on effcacy and safety. Expert Opin. Drug Discov.
13. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that infuence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615-2623 (2002).